European Journal of Clinical Pharmacology

, Volume 20, Issue 6, pp 479–483 | Cite as

Pharmacokinetic study of chloramphenicol in patients with liver disease

  • A. P. S. Narang
  • D. V. Datta
  • N. Nath
  • V. S. Mathur
Originals

Summary

The pharmacokinetics of intravenous chloramphenicol has been studied in 42 patients with liver disease and in 8 controls. The half-life of chloramphenicol (t1/2) was increased in the various liver disorders, the metabolic clearance rate (MCR) and apparent volume of distribution (Vd) were decreased and the area under the time — concentration curve (AUC) showed an increase. The t1/2 of chloramphenicol showed a significant correlation with serum albumin and prothrombin time index.

Key words

chloramphenicol liver disease pharmacokinetics intravenous administration serum albumin prothrombin time index 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Glazko AJ, Wolf LM, Dill WA (1949) Biochemical studies on chloramphenicol (chloromycetin). I. Colorimetric methods for the determination of chloramphenicol and related compounds. Arch Biochem 23: 411–418Google Scholar
  2. 2.
    Ley HL, Jr., Smadel JE, Crocker TT (1948) Administration of chloromycetin to normal human subjects. Proc Soc Exp Biol 68: 9–12Google Scholar
  3. 3.
    Smith JA, Butler TC, Poole DT (1973) Effect of protein depletion in guinea pigs on glucuronate conjugation of chloramphenicol by liver microsomes. Biochem Pharmacol 22: 981–983Google Scholar
  4. 4.
    Mehta S, Kalsi HK, Jayaraman S, Mathur VS (1975) Chloramphenicol metabolism in children with protein — calorie malnutrition. Am J Clin Nutr 28: 977–981Google Scholar
  5. 5.
    Kunin CM, Glazko AJ, Finland M (1959) Persistance of antibiotic with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis. J Clin Invest 38: 1498–1508Google Scholar
  6. 6.
    Azzollini F, Gazzaniga A, Lodola E, Natangelo R (1972) Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver. Int. J Clin Pharmacol 6: 130–134Google Scholar
  7. 7.
    Shurland LG, Weisberger AL (1963) Chloramphenicol toxicity in liver and renal disease. Arch Intern Med 112: 747–754Google Scholar
  8. 8.
    Dameshek W (1969) Chloramphenicol aplastic anemia in identical twins. A clue to pathogenesis. N Engl J Med 281: 42–43Google Scholar
  9. 9.
    Levine PH, Regelson W, Holland JF (1970) Chloramphenicol associate encephalopathy. Clin Pharmacol Ther 11: 194–199Google Scholar
  10. 10.
    Craft AW, Brocklebank JT, Hay EN, Jackson RH (1974) The ‘grey todder’ chloramphenicol toxicity. Arch Dis Childh 49: 235–237Google Scholar
  11. 11.
    Levine J, Fischback H (1951) The chemical determination of chloramphenicol in biological materials. Antibio Chemother 38: 59–65Google Scholar
  12. 12.
    Notari RE, DeYoung JL, Anderson RC (1975) Biopharmaceutics and Pharmacokinetics. An introduction. 2nd edit. Marcel Dekker, New YorkGoogle Scholar
  13. 13.
    Lindberg AA, Nilsson LH, Bucht H, Kallings, LO (1966) Concentration of chloramphenicol in the urine and blood in relation to renal function. Br Med J 2: 724–728Google Scholar
  14. 14.
    Watanabe A (1974) Effect of chronic administration of centrally acting compounds on chloramphenicol metabolism in schizophrenic patients. Pharmacol 11: 253–256Google Scholar
  15. 15.
    Levy AJ, Sherlock S, Walker D (1968) Phenylbutazone and isosiazid metabolism in patients with liver disease in relation to previous durg therapy. Lancet 1: 1275–1279Google Scholar
  16. 16.
    Remmer H (1970) The Role of the liver in drug metabolism. Am J Med 49: 617–629Google Scholar
  17. 17.
    Datta, DV (1976) Review: Non-cirrhotic portal fibrosis (Idiopathic portal hypertension) in India. J Assoc Phys India 24: 511–527Google Scholar
  18. 18.
    Datta DV, Nair R, Nair CR (1975): Estimation of hepatic bilirubin UDP-glucuronyl transferase in patients with noncirrhotic portal fibrosis and liver disease. Significance and limitations. Am J Dig Dis 20: 961–971Google Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • A. P. S. Narang
    • 1
  • D. V. Datta
    • 1
  • N. Nath
    • 1
  • V. S. Mathur
    • 1
  1. 1.Departments of Hepatology and PharmacologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations